Flurbiprofen lozenges are relevant for easing symptoms related to inflammatory or irritative states in the throat. The medication is indicated for the short-term symptomatic relief of sore throat.

---

Acute Pain, Inflammation, and Symptom Management

This medication is applied across domains where additional symptomatic support is needed, primarily focusing on symptoms related to physical discomfort. It is commonly used when groups of symptoms, especially pain intensity, may become intense or disruptive, such as those associated with pharyngitis or tonsillo-pharyngitis.

The product is relevant for conditions characterized by acute or disruptive episodes, and generally helps address symptoms that create noticeable functional strain, such as discomfort related to swallowing. In essence, it supports the patient during difficult episodes.

“The product is often applied when symptoms interfere with routine activities to offer supportive relief.”

This product is applied in clinical settings that involve acute or unstable symptom patterns, and is commonly used to help with distressing manifestations for adults and adolescents.

Quick Fact	Symptomatic Support for Discomfort
Primary Indication	Symptomatic relief of sore throat
Symptom Cluster	Pain intensity, inflammation, swelling
Functional Benefit	Support for Functional Stability
Use Context	Acute or short-term symptomatic support

Regulatory References

1. Public Assessment Report by the Spanish Agency of Medicines (CIMA)

Eligibility Map: Who Can and Cannot Use Strepsils Dolo — Official Regulatory Information

This section describes only the population eligibility rules, restrictions, and contraindications for Strepsils Dolo (Flurbiprofen lozenges), as mandated by authoritative government regulatory documents.

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults
• Adolescents aged 12 years and over
• Patients with mild to moderate renal or hepatic impairment

Populations for whom use is not recommended (if applicable):

• Nursing mothers (Lactation)

Populations for whom use is contraindicated:

• Children under 12 years of age.
• Patients with known hypersensitivity to flurbiprofen, aspirin, or other NSAIDs.
• Females in the last trimester of pregnancy.
• Patients with severe heart failure, severe renal failure, or severe hepatic failure.
• Patients with active or history of recurrent peptic ulcer/haemorrhage.

Age-related eligibility rules:

• Minimum approved age: 12 years.
• Children under 12 years are contra-indicated; safety and efficacy have not been established.
• Older Adults (Elderly) may use, but regulators note an increased risk of adverse reactions.

Condition-specific eligibility rules:

• Severe Organ Failure: Contraindicated in severe hepatic, renal, or heart failure.
• Gastrointestinal History: Contraindicated with active or recurrent peptic ulceration/haemorrhage.

Pregnancy and lactation eligibility status (if explicitly documented):

• First and Second Trimester of Pregnancy: Should not be given unless clearly necessary.
• Last Trimester of Pregnancy: Contraindicated.

Eligibility-related restrictions:

• Use with caution in patients with a history of bronchial asthma or allergic disease.
• Use with care in patients with a history of Ulcerative Colitis or Crohn's Disease.

---

Connection to the overall eligibility profile

Official regulatory documents strictly define eligibility by categorizing populations into those who are contraindicated and those who are approved. The primary exclusions are driven by the systemic effects of the NSAID component, focusing on age restrictions, severe organ failure, history of bleeding or ulceration, and known hypersensitivity to NSAIDs.

Strepsils Dolo lozenges contain flurbiprofen, a Non-Steroidal Anti-Inflammatory Drug (NSAID). Due to the potential for systemic absorption, flurbiprofen carries the interaction risks associated with NSAIDs. It is generally recommended to avoid concomitant use with other NSAIDs, including selective cyclooxygenase-2 inhibitors and regular analgesic doses of Acetylsalicylic acid (aspirin), as this combination significantly increases the risk of serious adverse effects, particularly gastrointestinal bleeding and ulceration.

Flurbiprofen may also interact with several classes of prescription medicines, necessitating close medical monitoring or dose adjustments. Concomitant use with anticoagulants (like warfarin) or anti-platelet agents increases the risk of bleeding. The product may reduce the effectiveness of diuretics and certain anti-hypertensive drugs (e.g., ACE inhibitors, Angiotensin II Receptor Blockers, Beta-blockers). When combined with these medications, or with drugs like Ciclosporin or Corticosteroids, there is an increased risk of organ toxicity, especially in the kidneys. Flurbiprofen may also increase the plasma levels of Lithium and Methotrexate, raising the risk of toxicity from those medicines. Patients should inform their doctor or pharmacist of all concurrent medications, including non-prescription products and herbal supplements, before use.

Enzyme Inhibition: Suppressing Inflammatory Mediators

The core mechanism involves the active ingredient, Flurbiprofen, which functions as an active, non-selective inhibitor of the Cyclooxygenase (COX) enzymes (specifically COX-1 and COX-2) within the throat tissue. This action blocks the biochemical pathway that converts Arachidonic Acid into Prostaglandins, primarily Prostaglandin E2 (PGE2), which is a critical chemical mediator of acute inflammatory processes.

---

Modulating Nociceptive and Vascular Responses

By suppressing the production of PGE2, the drug's mechanism reduces two key physiological effects of inflammation: it reduces the chemical sensitization of local nerve endings (nociceptors) and decreases local vasodilation and fluid accumulation (edema). The specialized lozenge form ensures rapid absorption directly into the oropharyngeal mucosa, initiating the enzyme inhibition quickly for a focused, peripheral action that ultimately results in the physiological dampening of the nociceptive and vascular responses.

Administration Guidelines: Flurbiprofen 8.75 mg Lozenge

The usage of Strepsils Dolo is based on parameters regarding administration, dosing, and duration.

Administration and Dosing

The route of administration is oromucosal, meaning the 8.75 mg lozenge is intended for local delivery to the mouth and throat. This preparation is for short-term use only and is administered on an as-needed basis to control symptoms.

Feature	Instruction
Single Dose	One lozenge.
Dosing Frequency	One lozenge every 3 to 6 hours as required.
Daily Maximum	A maximum of 5 lozenges in any 24 hour period.
Max. Duration	Treatment is limited to a maximum of three days.

Procedural and Population Rules

For proper administration, the lozenge must be sucked/dissolved slowly in the mouth and should be continuously moved around while dissolving. This helps to minimize the risk of localized irritation. If a dose is missed, a double dose must not be taken to compensate.

Usage is restricted to adults and adolescents aged 12 years and older; the product is not indicated for use in children under 12 years of age. For older adults and patients with mild to moderate renal or hepatic impairment, no specific dose modification is required.

Strepsils Dolo: Recent Clinical Evidence

Strepsils Dolo lozenges contain the active ingredient flurbiprofen at a dose of 8.75 mg. Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) and is classified as a mixed cyclo-oxygenase (COX)-1/COX-2 inhibitor, a mechanism associated with reducing inflammation and pain locally in the throat.

---

Efficacy and Symptom Relief

Clinical studies have evaluated the use of flurbiprofen 8.75 mg lozenges for the short-term symptomatic relief of sore throat associated with upper respiratory tract infection (URTI). Findings from randomized, placebo-controlled trials indicate that the lozenge provides a statistically significant reduction in throat pain intensity and associated symptoms, such as difficulty swallowing and the sensation of a swollen throat, compared to placebo.

• Onset of Action: Relief from throat pain has been observed in some studies as early as 11 to 15 minutes after a single dose.
• Duration of Action: The pain-relieving effects have been reported to be sustained for up to 4 to 6 hours following administration.

These effects were noted in patients with moderate-to-severe sore throat symptoms and in specific subgroups, including those with confirmed streptococcal pharyngitis (strep throat) and patients receiving concomitant antibiotic therapy.

---

Safety and Tolerability

Flurbiprofen lozenges at the 8.75 mg dose have generally demonstrated a favorable tolerability profile in clinical studies over a treatment period of up to three to seven days.

The most commonly reported adverse events are local and gastrointestinal in nature, including taste disturbances, oral irritation, and mild nausea or abdominal pain. Studies did not report serious adverse events or discontinuations related to adverse events more frequently than with placebo. However, as with all NSAIDs, the potential for gastrointestinal or systemic side effects exists, particularly with chronic use or at higher doses.

Common questions about Strepsils Dolo (FAQ)

Q: Is Strepsils Dolo the same as regular Strepsils lozenges?

A: Strepsils Dolo lozenges contain flurbiprofen, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This pharmacological class is different from many other Strepsils products, which may contain antiseptic ingredients. The flurbiprofen in Strepsils Dolo provides a dual action of pain relief and anti-inflammatory action.

Q: Can Strepsils Dolo be used for a dry cough?

A: Official product information states that the medicine is indicated for the short-term relief of symptoms of sore throat, such as throat pain, soreness, swelling, and difficulty in swallowing. The documents do not list dry cough as a condition for which the product is indicated.

Q: Are there any common foods or drinks that should be avoided when using Strepsils Dolo?

A: Official guidance generally does not specify common foods or non-alcoholic drinks to avoid while using this medicine. However, regulatory documents advise that the use of alcohol may increase the risk of adverse reactions, particularly bleeding in the gastrointestinal tract, a known risk associated with NSAIDs.

Q: Does Strepsils Dolo interact with common cold medicines?

A: Regulatory documents advise avoiding concomitant use (taking at the same time) with other NSAIDs, including common doses of aspirin. This is because combining these medicines increases the potential for adverse effects, particularly gastrointestinal issues. Since many common over-the-counter cold and flu remedies contain NSAIDs or other painkillers, this situation often necessitates informing a pharmacist or doctor for a review.

Q: Is Strepsils Dolo meant for treating viral or bacterial infections?

A: Strepsils Dolo is an NSAID which relieves inflammation and pain; it is indicated only for the short-term relief of symptoms of a sore throat. The medicine does not treat the underlying viral or bacterial infection. Official warnings describe that if signs of a bacterial infection occur or worsen during use, a physician should be informed.

Q: Is an allergic reaction to Strepsils Dolo common?

A: Severe hypersensitivity reactions, such as anaphylaxis or angioedema, are classified as very rare in regulatory documents. Other hypersensitivity reactions, including a skin rash and itching, are classified as uncommon, meaning they may affect up to 1 in 100 people.

Q: Is it normal to feel a temporary numbness in the mouth after using a Strepsils Dolo lozenge?

A: Yes, a sensation of numbness in the throat is listed as an uncommon side effect in regulatory documents, meaning it may affect up to 1 in 100 people. Localized sensations, including tingling, are commonly reported as a form of oropharyngeal discomfort.

Q: Does Strepsils Dolo contain sugar?

A: The presence of sugar depends on the specific product formulation and flavor. Some standard flavors contain sugars such as glucose, sucrose, and invert sugar. However, sugar-free versions of the lozenges are also available, which typically use sweeteners like maltitol and isomalt. The ingredients must be confirmed by checking the specific product package.

Q: Are there different flavors of Strepsils Dolo available?

A: Yes. Official product information sheets and regulatory documents list the medicine in various flavors, which may include Honey and Lemon, Orange, and Eucalyptus and Manuka Honey, depending on the region and specific formulation.

Q: Why do some lozenges contain NSAIDs like the one in Strepsils Dolo?

A: The lozenge form is designed for delivery directly to the tissue in the mouth and throat (oropharyngeal mucosa). This localized method of administration aims to achieve a focused, peripheral effect by rapidly delivering the NSAID flurbiprofen to the inflamed area, thereby relieving pain and reducing swelling directly at the source of the sore throat.

Q: Can Strepsils Dolo be used for pain other than throat pain?

A: The official indication for Strepsils Dolo is strictly limited to the short-term symptomatic relief of sore throat in adults and adolescents aged 12 years and over. Official documents do not describe or support its use for pain in other parts of the body.

Q: Does using Strepsils Dolo affect blood pressure?

A: Regulatory documents note that NSAID treatment, as a class, has been associated with reports of high blood pressure (hypertension) and fluid retention (oedema). Caution is required when describing the use of this medicine, particularly for patients with a history of hypertension or heart failure.

Q: Can Strepsils Dolo affect the kidneys?

A: Regulatory warnings state that NSAIDs can potentially cause kidney damage (nephrotoxicity). However, for a short-term, limited-use product such as the lozenge, this effect is not usually seen. The risk is increased in patients with existing impaired renal function, the elderly, or those taking diuretics.

Q: Does Strepsils Dolo contain gluten or lactose?

A: Excipient information, which includes non-active ingredients, varies by product flavor and formulation. Some formulations are stated to contain only very low levels of gluten (from wheat starch) and are generally regarded as 'gluten-free.' Lactose is not typically an excipient. For patients with sensitivities, the excipient list on the specific package is the source of confirmation.

Q: Are there any known interactions between Strepsils Dolo and herbal supplements?

A: Regulatory documents list interactions with many prescription medicines but do not specify interactions with particular herbal supplements. Official documents contain a statement recommending that patients inform a healthcare professional of all concurrent medications, including non-prescription and herbal products.

Q: Can using Strepsils Dolo cause dizziness or drowsiness?

A: Yes. According to official adverse effects listings, dizziness is classified as a common side effect (may affect up to 1 in 10 people). Drowsiness (feeling sleepy) is listed as an uncommon side effect (may affect up to 1 in 100 people).

Q: Is it safe to drive after using a Strepsils Dolo lozenge?

A: Official patient information describes that if a patient experiences side effects such as dizziness, visual disturbances, or drowsiness, they may be impaired for driving or operating machines. These effects are classified as possible with the medicine.

Q: Can I use Strepsils Dolo if I have diabetes?

A: Caution is noted in official documents because the potential for this drug to interact with oral antidiabetics has been reported, sometimes requiring increased blood glucose monitoring. Additionally, the sugar content of the lozenge varies by flavor (sugar vs. sugar-free) and must be checked on the specific package.

Q: Why must certain people with existing health conditions avoid Strepsils Dolo?

A: The mandatory contraindications are primarily related to the systemic effects of the NSAID flurbiprofen. For example, it is avoided in those with a history of peptic ulcer or bleeding because NSAIDs can increase the risk of gastrointestinal bleeding. It is also contraindicated in patients with severe organ failure (heart, kidney, or liver) because NSAIDs can worsen these existing conditions.

Q: Is it common for people to report tingling after using Strepsils Dolo?

A: Yes. A tingling sensation, classified as an unusual sensation in the mouth or throat (paraesthesia), is listed as a common side effect (may affect up to 1 in 10 people). This sensation is classified as a local oropharyngeal discomfort.

How to Store and Dispose of Strepsils Dolo?

The storage and disposal of Strepsils Dolo 8.75 mg lozenges must comply strictly with regulatory requirements to maintain product stability and ensure environmental safety.

---

Storage Requirements

• Temperature and Protection: The product must be stored below 25 C and kept in the original outer carton for protection from both light and moisture.
• Packaging and Stability: Store the lozenges in their original packaging and do not use them after the expiry date (EXP) indicated on the pack.
• Child Safety: It is mandatory to keep this medicine out of the sight and reach of children at all times.

---

Disposal Instructions

Do not dispose of unused or expired Strepsils Dolo via wastewater or routine household waste. Official guidance mandates that medicines should be returned to a pharmacist for proper disposal, which is managed according to local pharmaceutical waste regulations.